Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 16/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723827 | 0.94 | CSF1R (0.64) | CSF1REGFRERBB2PDE4BNUDT1 | |
| SCHEMBL2723535 | 0.93 | CSF1R (0.61) | CSF1REGFRERBB2PDE4B | |
| SCHEMBL2725837 | 0.88 | CSF1R (0.61) | CSF1REGFRERBB2PDE4B | |
| SCHEMBL2723389 | 0.86 | CSF1R (0.71) | CSF1REGFRERBB2 | |
| SCHEMBL2725458 | 0.84 | CSF1R (0.59) | CSF1REGFRERBB2PDE4B | |
| SCHEMBL5930114 | 0.81 | CSF1R (0.81) | CSF1REGFRERBB2NUDT1 | |
| SCHEMBL2725153 | 0.79 | CSF1R (0.64) | CSF1REGFRERBB2PDE4B | |
| SCHEMBL2725816 | 0.79 | CYP3A4 (0.69) | CSF1REGFRERBB2PDE4B | |
| SCHEMBL2724277 | 0.79 | CSF1R (0.59) | CSF1REGFRERBB2PDE4B | |
| SCHEMBL29484297 | 0.79 | CYP3A4 (0.69) | CSF1REGFRERBB2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635279-A2 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012061557-A2 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225524-A1 | Chemical Compounds | LDHA, NQO2, LDHB | CSF1R 2683/4885EGFR 1772/4885ERBB2 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.